دورية أكاديمية
Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?
| العنوان: | Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading? |
|---|---|
| المؤلفون: | Juarez-Vignon Whaley JJ; Health Science Research Center, Faculty of Health Science, Universidad Anahuac Mexico, State of Mexico, Naucalpan de Juárez, Mexico., Afkhami M; Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Onyshchenko M; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, 1500 East Duarte Road. , Duarte, CA, 91010, USA., Massarelli E; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, 1500 East Duarte Road. , Duarte, CA, 91010, USA., Sampath S; Department of Radiation Oncology, City of Hope Comprehensive Cancer Center Duarte, Duarte, CA, USA., Amini A; Department of Radiation Oncology, City of Hope Comprehensive Cancer Center Duarte, Duarte, CA, USA., Bell D; Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Villaflor VM; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, 1500 East Duarte Road. , Duarte, CA, 91010, USA. vvillaflor@coh.org. |
| المصدر: | Current treatment options in oncology [Curr Treat Options Oncol] 2023 Sep; Vol. 24 (9), pp. 1138-1166. Date of Electronic Publication: 2023 Jun 15. |
| نوع المنشور: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Current Science, Inc Country of Publication: United States NLM ID: 100900946 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-6277 (Electronic) Linking ISSN: 15346277 NLM ISO Abbreviation: Curr Treat Options Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, PA : Current Science, Inc., |
| مواضيع طبية MeSH: | Epstein-Barr Virus Infections*/complications , Epstein-Barr Virus Infections*/pathology , Head and Neck Neoplasms* , Nasopharyngeal Neoplasms*/diagnosis , Nasopharyngeal Neoplasms*/etiology , Nasopharyngeal Neoplasms*/therapy, Humans ; Nasopharyngeal Carcinoma/diagnosis ; Nasopharyngeal Carcinoma/etiology ; Nasopharyngeal Carcinoma/therapy ; Herpesvirus 4, Human ; Neoplasm Recurrence, Local/therapy |
| مستخلص: | Opinion Statement: Nasopharyngeal carcinoma (NPC) is distinct in its anatomic location and biology from other epithelial head and neck cancer (HNC). There are 3 WHO subtypes, which considers the presence of Epstein-Barr virus (EBV) and other histopathology features. Despite the survival benefit obtained from modern treatment modalities and techniques specifically in the local and locally advanced setting, a number of patients with this disease will recur and subsequently die of distant metastasis, locoregional relapse, or both. In the recurrent setting, the ideal therapy approach continues to be a topic of discussion and current recommendations are platinum-based combination chemotherapy. Phase III clinical trials which led to the approval of pembrolizumab or nivolumab for head and neck squamous cell carcinoma (HNSCC) specifically excluded NPC. No immune checkpoint inhibitor therapy, to date, has been approved by the FDA to treat NPC although the National Comprehensive Cancer Network (NCCN) recommendations do include use of these agents. Hence, this remains the major challenge for treatment options. Nasopharyngeal carcinoma is challenging as it is really 3 different diseases, and much research is required to determine best options and sequencing of those options. This article is going to address the data to date and discuss ongoing research in EBV + and EBV - inoperable recurrent/metastatic NPC patients. (© 2023. The Author(s).) |
| References: | Ann Oncol. 2011 Jun;22(6):1280-1287. (PMID: 21317222) Am J Clin Oncol. 2012 Jun;35(3):255-60. (PMID: 21358293) Ann Oncol. 2011 Mar;22(3):718-722. (PMID: 20716628) Chin J Cancer. 2011 Dec;30(12):831-41. (PMID: 22059912) J Natl Cancer Inst. 2006 Mar 1;98(5):298-300. (PMID: 16507823) J Immunother. 2010 Nov-Dec;33(9):983-90. (PMID: 20948438) Int J Cancer. 2018 Jan 1;142(1):66-80. (PMID: 28857155) Cancer. 1998 Aug 1;83(3):582-8. (PMID: 9690553) Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):11283-11288. (PMID: 27647909) J Clin Oncol. 2007 Aug 20;25(24):3766-73. (PMID: 17704426) Curr Oncol. 2022 Aug 23;29(9):6035-6052. (PMID: 36135044) Head Neck. 2003 Oct;25(10):864-72. (PMID: 12966511) Ther Adv Med Oncol. 2022 May 7;14:17588359221096214. (PMID: 35547095) Expert Opin Biol Ther. 2019 Nov;19(11):1165-1172. (PMID: 31361154) J Virol. 2004 Jan;78(2):768-78. (PMID: 14694109) Eur J Epidemiol. 2014 Jan;29(1):35-48. (PMID: 24271556) Lancet. 2019 Jul 6;394(10192):64-80. (PMID: 31178151) J Clin Oncol. 2021 Oct 10;39(29):3273-3282. (PMID: 34379443) Cancer. 2005 Feb 1;103(3):576-81. (PMID: 15612023) J Clin Oncol. 2005 Feb 10;23(5):1011-27. (PMID: 15585754) Infect Agent Cancer. 2010 Sep 19;5:16. (PMID: 20849661) Hum Gene Ther Clin Dev. 2013 Sep;24(3):134-42. (PMID: 24099518) Front Oncol. 2022 Jun 17;12:880643. (PMID: 35785170) Ann Oncol. 2013 Apr;24(4):1055-61. (PMID: 23172635) Clin Nucl Med. 2018 Apr;43(4):287-288. (PMID: 29401153) Infect Agent Cancer. 2007 Oct 11;2:18. (PMID: 17931416) Front Oncol. 2021 Feb 16;10:610787. (PMID: 33665166) Head Neck. 2020 Aug;42(8):1970-1980. (PMID: 32154638) Ann Oncol. 2002 Jan;13(1):150-6. (PMID: 11865813) JAMA Oncol. 2020 Sep 1;6(9):1345-1352. (PMID: 32701129) Oncoimmunology. 2017 Jan 4;6(2):e1273311. (PMID: 28344888) Future Oncol. 2017 Feb;13(5):425-431. (PMID: 27875901) J Otolaryngol. 1991 Feb;20(1):27-9. (PMID: 1709423) Onco Targets Ther. 2019 Feb 26;12:1583-1591. (PMID: 30881013) Virchows Arch. 2002 Nov;441(5):444-8. (PMID: 12447673) Oncoimmunology. 2015 Mar 06;4(2):e976507. (PMID: 25949875) Int J Cancer. 2001 Oct 1;94(1):73-80. (PMID: 11668481) Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):20-4. (PMID: 25227762) Clin Cancer Res. 2018 Mar 1;24(5):1030-1037. (PMID: 29301831) Lancet Oncol. 2018 Oct;19(10):1338-1350. (PMID: 30213452) J Clin Oncol. 2005 May 20;23(15):3562-7. (PMID: 15908667) Nat Commun. 2022 Nov 23;13(1):7182. (PMID: 36418296) J Cancer Res Clin Oncol. 2012 Oct;138(10):1717-25. (PMID: 22684794) Nat Med. 2021 Sep;27(9):1536-1543. (PMID: 34341578) Br J Cancer. 2018 Apr;118(8):1051-1055. (PMID: 29555989) Oral Oncol. 2003 Jun;39(4):361-6. (PMID: 12676255) Lancet. 2016 Oct 15;388(10054):1883-1892. (PMID: 27567279) Cancer Med. 2020 Sep;9(17):6147-6158. (PMID: 32649056) Ann Oncol. 2012 Apr;23(4):997-1005. (PMID: 21821548) Nat Commun. 2021 Jan 5;12(1):117. (PMID: 33402692) Nat Rev Drug Discov. 2009 Jan;8(1):33-40. (PMID: 19116625) PLoS One. 2016 Jan 12;11(1):e0146771. (PMID: 26757277) J Biomed Sci. 2019 Feb 4;26(1):14. (PMID: 30717758) Nat Commun. 2017 Jan 18;8:14121. (PMID: 28098136) J Biomed Res. 2014 Nov;28(6):468-75. (PMID: 25469116) Cancer Res. 2002 Dec 1;62(23):6952-8. (PMID: 12460912) J Clin Oncol. 2005 May 20;23(15):3568-76. (PMID: 15809453) Clin Cancer Res. 2011 Aug 15;17(16):5481-9. (PMID: 21712450) Oral Oncol. 2021 Feb;113:105127. (PMID: 33454551) J Immunother. 2013 Apr;36(3):208-14. (PMID: 23502768) Cureus. 2019 Mar 9;11(3):e4210. (PMID: 31114729) Histopathology. 2002 Aug;41(2):144-51. (PMID: 12147092) Invest New Drugs. 2020 Dec;38(6):1847-1853. (PMID: 32363427) Trends Genet. 2014 Aug;30(8):326-39. (PMID: 25017190) J Clin Oncol. 2018 May 10;36(14):1412-1418. (PMID: 29584545) JAMA Oncol. 2022 Apr 01;8(4):553-561. (PMID: 35175316) Oncotarget. 2014 Dec 15;5(23):12189-202. (PMID: 25361008) Ann Oncol. 1999 Feb;10(2):235-7. (PMID: 10093695) J Clin Oncol. 2021 Mar 1;39(7):704-712. (PMID: 33492986) Semin Cancer Biol. 2002 Dec;12(6):431-41. (PMID: 12450729) Cancers (Basel). 2021 Sep 30;13(19):. (PMID: 34638429) Ann Oncol. 1998 Mar;9(3):327-9. (PMID: 9602268) Cancer Res. 2013 Mar 15;73(6):1676-88. (PMID: 23348421) J Immunother Cancer. 2021 Dec;9(12):. (PMID: 34933967) J BUON. 2008 Jan-Mar;13(1):37-42. (PMID: 18404784) Hum Vaccin Immunother. 2020 Oct 2;16(10):2389-2402. (PMID: 32078405) Nat Commun. 2021 Jul 7;12(1):4193. (PMID: 34234122) J Clin Oncol. 2017 Dec 20;35(36):4050-4056. (PMID: 28837405) Semin Cancer Biol. 2020 Apr;61:84-100. (PMID: 31521748) N Engl J Med. 2014 Jul 17;371(3):224-33. (PMID: 25014687) Eur J Cancer. 1998 Dec;34(13):2027-31. (PMID: 10070305) Sci Rep. 2017 Apr 7;7(1):721. (PMID: 28389658) Int J Cancer. 2019 May 1;144(9):2313-2319. (PMID: 30485420) CA Cancer J Clin. 2017 Mar;67(2):93-99. (PMID: 28094848) Cancer. 1996 Jun 15;77(12):2423-31. (PMID: 8640688) Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):120-130. (PMID: 32853711) J Cancer. 2011;2:341-6. (PMID: 21716854) Am Soc Clin Oncol Educ Book. 2014;:149-53. (PMID: 24857071) Laryngoscope. 2004 Jan;114(1):153-7. (PMID: 14710013) Nature. 2012 Mar 28;483(7391):570-5. (PMID: 22460902) Clin Cancer Res. 2014 Oct 1;20(19):5009-22. (PMID: 25124688) Mol Cancer Ther. 2013 Nov;12(11):2517-28. (PMID: 23979918) J Virol. 2016 Sep 12;90(19):8520-30. (PMID: 27440880) Head Neck. 2018 Jun;40(6):1245-1253. (PMID: 29493822) Clin Cancer Res. 2018 Feb 15;24(4):777-783. (PMID: 29191972) J Clin Oncol. 2005 Dec 10;23(35):8942-9. (PMID: 16204009) Cancer. 2017 Jul 15;123(14):2642-2650. (PMID: 28222215) Cancer Chemother Pharmacol. 2008 Jun;62(1):59-64. (PMID: 17762933) Chin Clin Oncol. 2016 Apr;5(2):22. (PMID: 27121882) Mol Ther. 2014 Jan;22(1):132-9. (PMID: 24297049) Int J Cancer. 2004 May 10;109(6):919-25. (PMID: 15027126) Blood. 2005 Mar 1;105(5):1898-904. (PMID: 15542583) Clin Nucl Med. 2019 Dec;44(12):989-990. (PMID: 31663867) Appl Bionics Biomech. 2022 Jan 27;2022:8537966. (PMID: 35126664) Nat Rev Drug Discov. 2004 May;3(5):391-400. (PMID: 15136787) Radiother Oncol. 2020 Jul;148:157-166. (PMID: 32388150) J Clin Oncol. 2003 May 15;21(10):1980-7. (PMID: 12743152) Virus Res. 2006 Jan;115(1):85-90. (PMID: 16139912) Lancet Oncol. 2021 Aug;22(8):1162-1174. (PMID: 34174189) Cancer Chemother Pharmacol. 2013 Feb;71(2):371-8. (PMID: 23143190) Nat Rev Drug Discov. 2015 Sep;14(9):642-62. (PMID: 26323545) Head Neck. 2008 Jul;30(7):863-7. (PMID: 18213730) Clin Cancer Res. 2002 Aug;8(8):2595-604. (PMID: 12171890) Cancer. 1993 Apr 15;71(8):2689-97. (PMID: 8453591) Ai Zheng. 2004 Dec;23(12):1666-70. (PMID: 15601557) |
| فهرسة مساهمة: | Keywords: Clinical trials; Epstein-Barr virus positivity; Immunotherapy; Management NPC; Nasopharyngeal carcinoma; Recurrent/metastatic disease; Targeted therapy |
| تواريخ الأحداث: | Date Created: 20230615 Date Completed: 20230905 Latest Revision: 20230913 |
| رمز التحديث: | 20230914 |
| مُعرف محوري في PubMed: | PMC10477128 |
| DOI: | 10.1007/s11864-023-01101-3 |
| PMID: | 37318724 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!